Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARCADIA: cabozantinib plus durvalumab in previously chemotherapy-treated advanced bladder carcinoma
2023-509821-29-00Phase 2Authorised
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Feb 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib and durvalumab in bladder cancer and transitional cell carcinoma (TCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall survival. Planned start Feb 2024; status: authorised.
02
Drugs
cabozantinibdurvalumab
03
Conditions
bladder cancertransitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-509821-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509821-29-00.